L'aspirine en prévention primaire chez les patients diabétiques
|Published in||Revue médicale suisse. 2010, vol. 6, no. 234, p. 244-248|
|Abstract||Several meta-analysis support the prescription of aspirin for primary prevention of cardiovascular events in patients at risk. Though diabetics are particularly prone to these complications, a review of the literature shows that they have fewer benefits from the protective effects of such treatment. In these patients, controlling dyslipidemia, blood pressure and glycemia remains the main aim. Prescription of aspirin, in combination with an already existing medication, should not be solely based on the presence of diabetes, but on the overall risk profile of the patient, as well as his motivation.|
|Keywords||Aspirin/*therapeutic use — Cardiovascular Diseases/etiology/*prevention & control — *Diabetes Complications — Humans — Platelet Aggregation Inhibitors/*therapeutic use — *Primary Prevention|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Diabète et régulation des gènes (36)|
|FUMEAUX, David et al. L'aspirine en prévention primaire chez les patients diabétiques. In: Revue médicale suisse, 2010, vol. 6, n° 234, p. 244-248. https://archive-ouverte.unige.ch/unige:20464|